Subacute treatment of carprofen facilitate splenocardiac resolution deficit in cardiac injury

J Leukoc Biol. 2018 Dec;104(6):1173-1186. doi: 10.1002/JLB.3A0618-223R. Epub 2018 Aug 26.

Abstract

Inflammation-limiting nonsteroidal pain relievers magnify myocardial infarction (MI) incidences and increase re-admission events in heart failure (HF) patients. However, the molecular and cellular mechanism of this provocative adverse effect is unclear. Our goal was to determine whether carprofen (CAP) impedes splenic leukocyte-directed acute inflammation-resolving response in cardiac injury. After subacute CAP treatment, mice were subjected to permanent coronary ligation maintaining MI- and naïve-controls. Spleen and left ventricle (LV) leukocytes were quantitated using flow cytometry pre- and 24 h post-MI. The inflammation resolution mediators were quantified using mass spectrometry while splenocardiac apoptosis and leukocyte phagocytosis were measured by immunofluorescence and ImageStream, respectively. Subacute CAP treatment promoted strain and cardiac dysfunction before MI and coronary occlusion showed signs of acute HF in CAP and MI-controls. Subacute CAP-injected mice had pre-activated splenic neutrophils, an over activated "don't eat me" signal (CD47) with reduced total Mϕs (F4/80+ ) and reparative Mϕs (F4/80/Ly6Clo /CD206) compared with control in LV and spleen. Post-MI, CAP pre-activated neutrophils (Ly6G+ ) were intensified and reduced reparative neutrophils (Ly6G+ /CD206+ ) and Mϕs (F4/80/Ly6Clo ) in LV was indicative of non-resolving inflammation compared with MI-control. Subacute CAP treatment deferred neutrophil phagocytosis functions in the spleen and LV and was more evident post-MI compared with MI-control. CAP pre-activated splenic neutrophils that tailored the Mϕ phagocytosis thereby increased splenocardiac leukocyte death. CAP over amplified COX-1 and COX-2 compared with MI-control and failed to limit prostaglandins and thromboxane in post-MI setting. Further, CAP reduced cardiac-protective epoxyeicosatrienoic acids and over amplified pyrogenic inflammatory cytokines and reduced reparative cytokines, thereby non-resolving inflammation.

Keywords: inflammation; leukocytes; myocardial infarction; resolution of inflammation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / toxicity*
  • Apoptosis / drug effects
  • Carbazoles / pharmacology
  • Carbazoles / toxicity*
  • Cyclooxygenase 1 / physiology
  • Cyclooxygenase 2 / drug effects
  • Cyclooxygenase 2 / physiology
  • Eicosanoids / metabolism
  • Heart Failure / etiology
  • Heart Ventricles / drug effects*
  • Heart Ventricles / immunology
  • Heart Ventricles / physiopathology
  • Inflammation / chemically induced*
  • Inflammation / etiology
  • Inflammation Mediators / metabolism
  • Leukocytes / drug effects*
  • Leukocytes / immunology
  • Macrophage Activation / drug effects
  • Membrane Proteins / antagonists & inhibitors
  • Membrane Proteins / physiology
  • Mice
  • Mice, Inbred C57BL
  • Myocardial Infarction / immunology
  • Myocardial Infarction / pathology
  • Myocardial Infarction / physiopathology*
  • Neutrophil Activation / drug effects
  • Phagocytosis / drug effects
  • Prostaglandins / metabolism
  • Spleen / drug effects*
  • Spleen / immunology
  • Spleen / physiopathology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Carbazoles
  • Eicosanoids
  • Inflammation Mediators
  • Membrane Proteins
  • Prostaglandins
  • Ptgs2 protein, mouse
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Ptgs1 protein, mouse
  • carprofen